
Insurer halts controversial anesthesia policy; Americans don’t associate HPV with throat cancer; AI for primary care curriculum – Morning Medical Update
Key Takeaways
- Anthem reversed its anesthesia reimbursement policy after backlash and criticism from the American Society of Anesthesiologists.
- Studies show less than one-third of Americans link HPV to throat cancer, with low HPV vaccination completion rates.
The top news stories in medicine today.
Last month, Anthem Blue Cross Blue Shield (Anthem) announced that, on plans in Connecticut, New York and Missouri, it would limit reimbursements for anesthesia during surgery and medical procedures, instead reimbursing doctors based on arbitrary time limits set by the insurer. The policy announcement initially went relatively unnoticed, with the exception of being condemned by the
“There has been significant, widespread misinformation about an update to our anesthesia policy,”
The human papillomavirus (HPV) is a common sexually transmitted infection (STI), and it also accounts for 70% of all threat cancers, according to the National Cancer Institute. Dispute commonly being associated with cervical cancer, throat cancer is now the most common HPV-related cancer. However, according to two recent studies from the University of Southern California (USC) Head and Neck Center and the USC Caruso Department of Otolaryngology – Head and Neck Surgery, less than one-third of Americans associate HPV with throat cancer, and less than 7% of adults eligible for the HPV vaccine have completed the vaccine’s full three-dose-course.
“This data is very worrisome because knowledge is the first step toward disease prevention,” Daniel Kwon, MD, a head and neck surgeon with Keck Medicine, said in a
Together with the Society of Teachers of Family Medicine and American Board of Family Medicine, the
The curriculum will consist of 5 modules, covering the essentials, social and ethical implications, evidence-based evaluation of tools, enhanced clinical encounters and integration into the clinic—all of which are designed for those with minimal AI/ML experience. AiM-PC will be launched in stages, beginning in late 2024, through Spring 2025. Find the
Newsletter
Stay informed and empowered with Medical Economics enewsletter, delivering expert insights, financial strategies, practice management tips and technology trends — tailored for today’s physicians.


















